ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 509,967 shares of the biotechnology company's stock after selling 26,020 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.22% of ADMA Biologics worth $10,194,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ADMA. Healthcare of Ontario Pension Plan Trust Fund grew its stake in ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after purchasing an additional 80,400 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock valued at $69,454,000 after purchasing an additional 92,281 shares during the period. Citigroup Inc. grew its holdings in ADMA Biologics by 251.7% during the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock worth $7,741,000 after acquiring an additional 277,138 shares during the period. Seven Eight Capital LP acquired a new stake in ADMA Biologics during the second quarter worth about $1,992,000. Finally, Principal Financial Group Inc. grew its holdings in ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after acquiring an additional 1,059,394 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on ADMA shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright raised their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Finally, Raymond James raised their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.70% of the company's stock.

ADMA Biologics Price Performance

ADMA stock traded down $0.81 during mid-day trading on Monday, reaching $19.01. 3,041,177 shares of the company's stock were exchanged, compared to its average volume of 3,606,414. The company has a market cap of $4.49 billion, a price-to-earnings ratio of 67.89 and a beta of 0.70. The stock's 50 day moving average is $19.08 and its 200 day moving average is $15.83. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 12-month low of $3.60 and a 12-month high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the prior year, the business posted $0.01 earnings per share. On average, research analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.